Litcius/Paper detail

Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial

Rafael Emilio de Feria Cardet, Michael S. Hofman, Tatiana Segard, Jackie Yim, Scott Williams, Roslyn J. Francis, Mark Frydenberg, Nathan Lawrentschuk, Declan G. Murphy, Richard De Abreu Lourenço

2020European Urology97 citationsDOIOpen Access PDF

Topics & Concepts

MedicineProstate cancerPositron emission tomographyProstateGlutamate carboxypeptidase IIRadiologyCost effectivenessNuclear medicinePositron Emission Tomography-Computed TomographyMedical imagingCancerInternal medicineRisk analysis (engineering)Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications
Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial | Litcius